|
US4160452A
(en)
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
US5169645A
(en)
|
1989-10-31 |
1992-12-08 |
Duquesne University Of The Holy Ghost |
Directly compressible granules having improved flow properties
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
ATE173159T1
(de)
|
1992-03-25 |
1998-11-15 |
Depomed Systems Inc |
Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
|
|
WO1997047285A1
(en)
|
1996-06-10 |
1997-12-18 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
WO1998033501A1
(en)
|
1997-01-31 |
1998-08-06 |
Avid Therapeutics Inc. |
2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
CA2290624C
(en)
|
1997-06-06 |
2006-12-05 |
John W. Shell |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
US6323219B1
(en)
|
1998-04-02 |
2001-11-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods for treating immunomediated inflammatory disorders
|
|
CA2389236A1
(en)
|
1999-11-02 |
2001-05-10 |
Depomed, Inc. |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
PT1233943E
(pt)
*
|
1999-11-24 |
2011-09-01 |
Sugen Inc |
Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
|
|
ES2270982T3
(es)
|
2000-02-04 |
2007-04-16 |
Depomed, Inc. |
Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
JP2004532259A
(ja)
|
2001-05-29 |
2004-10-21 |
デポメッド ディベロップメント リミティド |
胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
PT2609923T
(pt)
|
2010-03-31 |
2017-08-30 |
Gilead Pharmasset Llc |
Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
|
|
WO2012047856A2
(en)
|
2010-10-04 |
2012-04-12 |
Institute For Hepatitis And Virus Research |
Novel inhibitors of secretion of hepatitis b virus antigens
|
|
HRP20181564T1
(hr)
|
2011-06-30 |
2018-11-30 |
Arrowhead Pharmaceuticals, Inc. |
Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
|
|
EP3085368A1
(en)
|
2011-07-01 |
2016-10-26 |
Baruch S. Blumberg Institute |
Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
|
|
WO2013096744A1
(en)
|
2011-12-21 |
2013-06-27 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
|
CN104822267B
(zh)
|
2012-02-29 |
2018-01-23 |
巴鲁克·S·布伦博格研究所 |
乙型肝炎病毒共价闭合环状dna形成的抑制剂及其使用方法
|
|
EP2831060B1
(en)
|
2012-03-31 |
2016-05-04 |
F.Hoffmann-La Roche Ag |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
EA038942B1
(ru)
|
2012-08-28 |
2021-11-12 |
Янссен Сайенсиз Айрлэнд Юси |
Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
EA026957B1
(ru)
|
2012-08-28 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
CA2892606A1
(en)
|
2012-12-06 |
2014-06-12 |
Baruch S. Blumberg Institute |
Functionalized benzamide derivatives as antiviral agents against hbv infection
|
|
CN105209031A
(zh)
|
2012-12-27 |
2015-12-30 |
德雷克塞尔大学 |
针对hbv感染的新型抗病毒剂
|
|
HUE034820T2
(en)
|
2013-02-28 |
2018-02-28 |
Janssen Sciences Ireland Uc |
Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
US9187454B2
(en)
*
|
2013-03-13 |
2015-11-17 |
Boston Biomedical, Inc. |
Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
|
|
EA027068B1
(ru)
|
2013-04-03 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
EA035500B1
(ru)
|
2013-05-17 |
2020-06-25 |
Янссен Сайенсиз Айрлэнд Юси |
Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
|
|
TWI651300B
(zh)
|
2013-05-17 |
2019-02-21 |
健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
JP6333372B2
(ja)
|
2013-07-09 |
2018-05-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃ型肝炎ウイルス阻害剤の組み合わせ
|
|
DK3024819T3
(en)
|
2013-07-25 |
2018-06-06 |
Janssen Sciences Ireland Uc |
GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
AU2014348518B2
(en)
|
2013-11-14 |
2019-01-03 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
EA201691261A1
(ru)
|
2014-01-30 |
2016-11-30 |
Ф. Хоффманн-Ля Рош Аг |
Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
|
|
WO2015118057A1
(en)
|
2014-02-06 |
2015-08-13 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
JP6306750B2
(ja)
|
2014-03-07 |
2018-04-04 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン
|
|
PT3116316T
(pt)
|
2014-03-13 |
2019-09-30 |
Assembly Biosciences Inc |
Moduladores alostéricos da proteína do núcleo da hepatite b
|
|
RU2016146365A
(ru)
|
2014-05-13 |
2018-06-19 |
Ф. Хоффманн-Ля Рош Аг |
Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
|
|
BR112016028000B1
(pt)
|
2014-05-30 |
2022-05-17 |
Qilu Pharmaceutical Co., Ltd |
Derivado de alça de di-hidropirimido como um inibidor de hbv
|
|
CN105367550A
(zh)
*
|
2014-08-11 |
2016-03-02 |
江苏柯菲平医药股份有限公司 |
四氢环戊二烯并[c]吡咯类衍生物、其制备方法及其在医药上的应用
|
|
JP6506836B2
(ja)
|
2014-08-14 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
WO2016089990A1
(en)
|
2014-12-02 |
2016-06-09 |
Novira Therapeutics, Inc. |
Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
|
|
WO2016107832A1
(en)
|
2014-12-30 |
2016-07-07 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
|
|
CN107207505B
(zh)
|
2015-02-11 |
2018-12-14 |
豪夫迈·罗氏有限公司 |
治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
|
|
WO2016177655A1
(en)
|
2015-05-04 |
2016-11-10 |
F. Hoffmann-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US10875876B2
(en)
*
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
JP6598974B2
(ja)
|
2015-07-21 |
2019-10-30 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症の治療および予防のための新規な三環式４−ピリドン−３−カルボン酸誘導体
|
|
WO2017015451A1
(en)
|
2015-07-22 |
2017-01-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017016960A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
|
|
WO2017016921A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
JP6506880B2
(ja)
|
2015-07-27 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
|
|
JP6559324B2
(ja)
|
2015-07-28 |
2019-08-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
|
|
TWI730985B
(zh)
|
2015-09-15 |
2021-06-21 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
WO2017064156A1
(en)
|
2015-10-16 |
2017-04-20 |
F. Hoffmann-La Roche Ag |
Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2017102648A1
(en)
|
2015-12-15 |
2017-06-22 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
|
|
ES2916874T3
(es)
|
2015-12-17 |
2022-07-06 |
Incyte Corp |
Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
|
|
WO2017108630A1
(en)
|
2015-12-21 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
|
|
WO2017114812A1
(en)
|
2015-12-29 |
2017-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an interferon
|
|
US20200270265A1
(en)
|
2016-02-19 |
2020-08-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
SG10202008301UA
(en)
|
2016-04-11 |
2020-10-29 |
Arbutus Biopharma Corp |
Targeted nucleic acid conjugate compositions
|
|
AU2017305399A1
(en)
|
2016-08-03 |
2019-01-31 |
Arising International, Inc. |
Symmetric or semi-symmetric compounds useful as immunomodulators
|
|
JOP20190024A1
(ar)
*
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
ES2941716T3
(es)
|
2016-08-29 |
2023-05-25 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2018045142A1
(en)
|
2016-09-02 |
2018-03-08 |
Polaris Pharmaceuticals, Inc. |
Immune checkpoint inhibitors, compositions and methods thereof
|
|
TWI794190B
(zh)
|
2016-11-07 |
2023-03-01 |
加拿大商愛彼特生物製藥公司 |
含有取代的吡啶酮之三環化合物及其使用方法
|
|
JP7106572B2
(ja)
|
2016-12-20 |
2022-07-26 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な化合物
|
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
|
AU2017382870B2
(en)
|
2016-12-22 |
2022-03-24 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
|
WO2018119286A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
|
EP3564237A4
(en)
|
2016-12-29 |
2020-06-10 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
|
|
WO2018133845A1
(zh)
*
|
2017-01-23 |
2018-07-26 |
上海长森药业有限公司 |
硫脲类、脲类化合物及其用途
|
|
CN109678796B
(zh)
|
2017-10-19 |
2023-01-10 |
上海长森药业有限公司 |
Pd-1/pd-l1小分子抑制剂及其制备方法和用途
|
|
KR20200085836A
(ko)
|
2017-11-06 |
2020-07-15 |
주빌런트 프로델 엘엘씨 |
Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
|